Yasunobu Sekiguchi Mutsumi Wakabayashi Haruko Takizawa Hiroko Iizuka Sakura Sakajiri Keiji Sugimoto Tadaaki Inano Yasutaka Fukuda Yasuharu Hamano Shigeki Tomita Hiroshi Izumi Mitsuo Okubo Noriko Nakamura Tomohiro Sawada Norio Komatsu Masaaki Noguchi
10.3960/jslrt.18031
J Clin Exp Hematop
2020;60(1):26-28.
forodesine peripheral t-cell lymphoma (ptcl) pralatrexate (pdx) relapse/refractory retreatment
CC BY-NC-SA
https://pubmed.ncbi.nlm.nih.gov/32224563/
Aminopterin / analogs & derivatives Antineoplastic Agents / therapeutic use Lymphoma, T-Cell, Peripheral / drug therapy Neoplasm Recurrence, Local / drug therapy Purine Nucleosides / therapeutic use Pyrimidinones / therapeutic use
Aminopterin / analogs & derivatives Antineoplastic Agents / therapeutic use Lymphoma, T-Cell, Peripheral / drug therapy Neoplasm Recurrence, Local / drug therapy Purine Nucleosides / therapeutic use Pyrimidinones / therapeutic use Case Reports Aged Aminopterin / therapeutic use Antineoplastic Combined Chemotherapy Protocols / therapeutic use Cyclophosphamide / therapeutic use Doxorubicin / therapeutic use Female Humans Lymph Nodes / drug effects Lymph Nodes / pathology Lymphoma, T-Cell, Peripheral / pathology Neoplasm Recurrence, Local / pathology Prednisone / therapeutic use T-Lymphocytes, Helper-Inducer / drug effects T-Lymphocytes, Helper-Inducer / pathology Vincristine / therapeutic use 10-propargyl-10-deazaaminopterin Antineoplastic Agents Purine Nucleosides Pyrimidinones forodesine Vincristine Doxorubicin Cyclophosphamide Aminopterin Prednisone CHOP protocol COP protocol 2
PMC7187677
32224563
Relapsed refractory nodal peripheral T-cell lymphoma with follicular helper T-cell phenotype was initially resistant to pralatrexate and confirmed to be unresponsive to subsequent forodesine, but responded to re-instituted pralatrexate
2020